[pubmed] Low-dose rituximab lowers serum Exosomal miR-150-5p in AChR-positive refractory myasthenia gravis patients
Posté : 22 sept. 2020 12:00
J Neuroimmunol. 2020 Sep 15;348:577383. doi: 10.1016/j.jneuroim.2020.577383. Online ahead of print.
ABSTRACT
Two potentially related microRNAs (miRNAs; miR-150-5p and miR-146a-5p) were examined after low-dose rituximab (RTX) treatment in patients with acetylcholine receptor antibody (AChR)-positive refractory myasthenia gravis (MG). In this prospective, open-label, and self-controlled pilot trial, 12 AChR-positive refractory MG patients were administrated a single, low dose of RTX and followed up at six months. Results showed that RTX decreased the serum exosomal miR-150-5p, scores on three clinical indices (MGFA, MMT, ADL), and patients' prednisolone requirement. Additionally, CD19+ and CD27+ B cells decreased, showing a strong correlation with miR-150-5p. In conclusion, low-dose RTX is effective for AChR-positive refractory MG treatment. Furthermore, our data support the role of miR-150-5p as a potential biomarker for MG.
PMID:32961347 | DOI:10.1016/j.jneuroim.2020.577383
Source: https://pubmed.ncbi.nlm.nih.gov/3296134 ... 7&v=2.11.5